Taylor Morrison
TMHC
$56.78
-2.51%
Taylor Morrison Home Corporation is a prominent American residential construction company that designs, builds, and sells single-family and multi-family homes, primarily in high-growth markets across the East, Central, and West regions of the United States. The company operates as a significant national homebuilder with a focus on entry-level, move-up, and resort lifestyle buyers, distinguishing itself through its development of lifestyle communities. The current investor narrative revolves around the stock's performance relative to the broader housing market and economic cycle, as evidenced by its significant underperformance against the S&P 500 over the past year, prompting debate on its resilience and valuation amidst potential interest rate and demand headwinds.…
TMHC
Taylor Morrison
$56.78
Investment Opinion: Should I buy TMHC Today?
Rating & Thesis: Hold. TMHC presents a compelling value profile with a strong balance sheet, but its near-term trajectory is too heavily dependent on an uncertain housing cycle recovery, warranting caution until clearer catalysts emerge. The limited analyst coverage provides no consensus price target to anchor a strong buy or sell thesis.
Supporting Evidence: The valuation is undeniably cheap, with a forward P/E of 9.81x, a P/B below 1 at 0.92x, and a P/S of 0.72x. The company's financial health is excellent, evidenced by a debt-to-equity ratio of 0.37 and a current ratio of 6.24. Profitability metrics are solid, with a 12.4% ROE and a 9.63% net margin. However, these strengths are counterbalanced by severe technical underperformance (-21.82 one-year relative strength) and high volatility (beta of 1.581), which increase the risk profile.
Risks & Conditions: The two biggest risks are a further deterioration in housing demand compressing earnings, and a broader market sell-off amplifying losses due to the high beta. This Hold rating would upgrade to a Buy if the stock demonstrates sustained technical strength by breaking above $72.5 resistance, or if forward P/E compresses further towards 8x without a corresponding drop in earnings estimates. It would downgrade to a Sell if quarterly earnings trend toward the low-end estimate of $5.03 EPS, or if the stock breaks below the $54.58 support level. On balance, the stock appears fairly valued to slightly undervalued relative to its own asset base and profitability, but overvalued relative to near-term cyclical risks.
Sign up to view all
TMHC 12-Month Price Forecast
TMHC is a high-quality company trapped in a disliked sector. The fundamentals support a value investment, but the technicals and macro backdrop argue for caution. The neutral stance reflects this tug-of-war; the stock is too cheap to sell aggressively but lacks a clear near-term catalyst to buy aggressively. Confidence is medium due to the limited analyst coverage, which increases uncertainty. The stance would upgrade to bullish on a confirmed housing data recovery and a technical breakout above $72.5. It would turn bearish if earnings deteriorate toward the low-end estimates or the stock loses its $54.58 support, signaling a new downtrend.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Taylor Morrison's 12-month outlook, with a consensus price target around $73.81 and implied upside of +30.0% versus the current price.
Average Target
$73.81
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$45 - $74
Analyst target range
Analyst coverage for TMHC is limited, with only 5 analysts providing estimates, which is typical for a mid-cap homebuilder and can lead to higher volatility and less efficient price discovery. The consensus estimates point to significant earnings growth, with an average EPS forecast of $6.58 for the coming year, ranging from a low of $5.03 to a high of $7.10, indicating a degree of uncertainty but overall positive expectations. Revenue estimates are tightly clustered around $7.15 billion, with a low of $7.05 billion and a high of $7.31 billion, suggesting stronger conviction on the top-line trajectory. The absence of explicit price targets, buy/hold/sell ratings, or institutional rating trends in the provided data prevents a calculation of implied upside/downside or a clear read on sentiment strength. The wide range in EPS estimates (a 41% spread from low to high) signals meaningful uncertainty among the covering analysts regarding the company's future earnings power, likely tied to divergent views on housing demand, interest rates, and input costs. This limited and divergent coverage environment requires investors to conduct more independent due diligence.
Bulls vs Bears: TMHC Investment Factors
The investment debate for TMHC hinges on a classic value versus cycle tension. The bull case is grounded in undeniable value: a profitable company with a fortress balance sheet trading at a deep discount to book value and with a low earnings multiple. The bear case is equally compelling, rooted in macro reality: the stock's severe underperformance and high volatility reflect justified fears about the housing cycle's sustainability. Currently, the bearish evidence holds stronger sway, as the market's punishing valuation discount and persistent technical weakness are direct results of ongoing sector headwinds. The single most important factor is the direction of interest rates and housing demand metrics; a decisive improvement here would validate the value thesis and trigger significant multiple expansion, while further deterioration would confirm the cyclical fears and could push the stock toward its 52-week low.
Bullish
- Deep Value Multiples: The stock trades at a forward P/E of 9.81x, a P/B of 0.92x, and a P/S of 0.72x, all at a significant discount to its asset value and typical homebuilder upcycle valuations. This suggests the market is pricing in severe cyclical headwinds, leaving substantial room for multiple expansion if the housing outlook stabilizes.
- Strong Balance Sheet & Liquidity: A low debt-to-equity ratio of 0.37 and a robust current ratio of 6.24 provide a significant financial cushion. This conservative capital structure minimizes risk and provides operational flexibility to navigate a downturn or capitalize on land acquisition opportunities.
- Solid Profitability Metrics: The company maintains a healthy net margin of 9.63% and a gross margin of 23.03%, demonstrating effective cost control. A Return on Equity of 12.4% indicates efficient use of shareholder capital to generate profits despite a challenging environment.
- Analyst Expectations for EPS Growth: Analysts forecast average EPS of $6.58 for the coming year, representing significant growth from the trailing figure. The forward P/E of 9.81x, while higher than the trailing multiple, is still low and implies the market is not fully pricing in this projected earnings recovery.
Bearish
- Severe Market Underperformance: TMHC has dramatically underperformed the broader market, gaining only 8.77% over the past year versus the S&P 500's 30.59% surge, resulting in a -21.82 relative strength. This indicates a strong, persistent negative sector rotation and lack of investor conviction in the housing cycle.
- High Volatility & Cyclical Risk: With a beta of 1.581, the stock is 58% more volatile than the market, amplifying downside risk during economic uncertainty. The stock has already experienced a maximum drawdown of -22.2%, highlighting its sensitivity to macro and interest rate fears.
- Limited Analyst Coverage & High Uncertainty: Only 5 analysts cover the stock, leading to less efficient price discovery. The wide range in EPS estimates, from $5.03 to $7.10 (a 41% spread), signals high uncertainty and divergent views on the company's near-term earnings power amidst housing market volatility.
- Valuation Discount Reflects Sector Headwinds: The deep discount on P/E, P/B, and P/S multiples is not an anomaly but a rational market response to sector-wide pressures. Until there is clear evidence of a sustained housing recovery, these depressed multiples may persist or worsen, capping upside.
TMHC Technical Analysis
The stock is in a pronounced downtrend relative to the market, having gained only 8.77% over the past year compared to the S&P 500's 30.59% surge, resulting in a severe relative strength reading of -21.82. Currently trading at $63.24, the price sits approximately 13% below its 52-week high of $72.5, indicating it is in the lower-middle portion of its annual range and suggesting a lack of bullish momentum. Recent short-term momentum shows a modest recovery, with the stock up 6.25% over the past month, which contrasts with its weak yearly performance and could signal a potential stabilization or mean reversion attempt. However, this one-month gain still lags the S&P 500's 8.7% advance, as reflected in the negative one-month relative strength of -2.45, indicating the rebound is tepid and not driven by sector leadership. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $72.5 and major support at the 52-week low of $54.58. A decisive breakout above $72.5 would be required to signal a reversal of the long-term underperformance, while a breakdown below $54.58 would confirm a new leg down in the bearish trend. The stock exhibits high volatility, with a beta of 1.581 indicating it is approximately 58% more volatile than the broader market, which is critical for risk management as it implies amplified moves during market swings, as seen in its maximum drawdown of -22.2%.
Beta
1.51
1.51x market volatility
Max Drawdown
-22.2%
Largest decline past year
52-Week Range
$55-$73
Price range past year
Annual Return
-7.3%
Cumulative gain past year
| Period | TMHC Return | S&P 500 |
|---|---|---|
| 1m | -5.8% | +8.2% |
| 3m | -13.3% | +9.0% |
| 6m | -4.9% | +10.5% |
| 1y | -7.3% | +26.5% |
| ytd | -3.5% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMHC Fundamental Analysis
Revenue trajectory analysis is constrained as specific quarterly revenue and growth rate figures are not available in the provided data. However, analyst estimates provide a forward-looking view, with average revenue expectations of $7.15 billion, ranging from a low of $7.05 billion to a high of $7.31 billion, suggesting the market anticipates stable, mid-single-digit growth from current levels. The company's profitability is solid, with a net margin of 9.63% and a gross margin of 23.03%, indicating effective cost control in its homebuilding operations. The trailing Price-to-Earnings (P/E) ratio of 7.45, derived from the provided EPS of $0.134, points to strong earnings generation, though the disconnect between this low P/E and the EPS figure suggests the reported EPS may not be annualized or fully representative; the forward P/E of 9.81 based on estimated EPS of $6.58 implies the market expects significant earnings growth. Balance sheet health appears robust, with a strong current ratio of 6.24 signaling ample short-term liquidity to cover obligations. The conservative capital structure is highlighted by a low debt-to-equity ratio of 0.37, which minimizes financial risk and provides flexibility. Return metrics are healthy, with a Return on Equity (ROE) of 12.4% and a Return on Assets (ROA) of 6.62%, demonstrating efficient use of shareholder capital and assets to generate profits.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMHC Overvalued?
Given the company's clear profitability with a positive net margin, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E is 7.45x, while the forward P/E is 9.81x, based on an estimated EPS of $6.58; the higher forward multiple indicates the market is pricing in expectations for meaningful earnings growth in the coming year. Compared to typical homebuilder valuations, which often trade at low-to-mid single-digit P/Es during downturns and mid-teens during upcycles, TMHC's sub-10x forward P/E appears to be at a discount, potentially reflecting concerns over the housing cycle's sustainability rather than its own operational strength. Historical context for the valuation is limited as specific historical ratio data is not provided. However, the current Price-to-Sales (P/S) ratio of 0.72 and Price-to-Book (P/B) ratio of 0.92 suggest the stock is valued below its theoretical asset replacement cost. This combination of low absolute multiples (P/E, P/S, P/B) and a discount to book value typically signals the market is assigning a value-oriented or cautious rating, possibly due to macroeconomic headwinds impacting the entire sector.
PE
7.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: TMHC's primary financial risk is not insolvency—its balance sheet is strong—but earnings volatility tied to the hyper-cyclical housing market. The company's profitability (9.63% net margin) is healthy but directly exposed to fluctuations in home prices, construction costs, and mortgage rates. While revenue estimates are tightly clustered around $7.15B, the wide 41% spread in analyst EPS forecasts ($5.03 to $7.10) quantifies the extreme uncertainty in its near-term earnings power. Furthermore, its high beta of 1.581 means its financial results and stock price will be disproportionately impacted by broader economic swings.
Market & Competitive Risks: The stock faces acute valuation compression risk, as its current low multiples could decline further if the housing downturn deepens. It trades at a significant discount to its own book value (P/B of 0.92), indicating the market fears asset impairment or prolonged undervaluation. Competitive risks are inherent in a fragmented industry, but the larger threat is macro: the stock's -21.82 one-year relative strength shows it is being aggressively sold off in favor of other sectors. Any resurgence in interest rate fears or a recession would likely trigger another severe leg down.
Worst-Case Scenario: The worst-case scenario involves a sharp economic contraction coupled with sustained high mortgage rates, leading to a severe drop in housing demand and prices. This would pressure TMHC's margins, potentially leading to inventory writedowns and missed earnings estimates at the low end ($5.03 EPS). In this scenario, the stock could re-test and break below its 52-week low of $54.58. From the current price of $63.24, this represents a realistic downside of approximately -14%. A breach of that support could trigger a steeper decline towards the $50 level, implying a total potential loss of -20% to -25% from current levels.
FAQ
The key risks are: 1) Macroeconomic & Interest Rate Risk: As a homebuilder, TMHC is hyper-sensitive to mortgage rates and economic health, reflected in its high beta of 1.581. 2) Cyclical Downturn Risk: Prolonged weak housing demand could push earnings toward the analyst low estimate of $5.03 EPS, justifying even lower valuations. 3) Market Sentiment Risk: The stock's severe underperformance (-21.82 RS vs. S&P 500) shows it is out of favor; this negative momentum can persist independently of fundamentals. 4) Limited Coverage Risk: With only 5 analysts, news and earnings can cause disproportionate price swings due to less efficient price discovery.
The 12-month forecast is bifurcated by scenario. The base case (60% probability) sees range-bound trading between $63 and $70 as the company delivers consensus EPS of ~$6.58 amidst a sluggish housing market. The bull case (25% probability) targets $72.5 to $78 on a housing recovery and earnings beat, driving P/E expansion. The bear case (15% probability) risks a fall to the $54.58-$60 range if earnings disappoint and cyclical fears intensify. The base case is most likely, anchored by the company's solid fundamentals but capped by persistent sector headwinds. The key variable is the direction of housing demand and interest rates.
Based on absolute multiples, TMHC appears significantly undervalued. It trades at a forward P/E of 9.81x, a Price-to-Sales of 0.72x, and, most notably, a Price-to-Book of 0.92x, meaning the market values it below its stated net asset value. Compared to historical homebuilder valuations during stable periods, this is a discount. However, this 'undervaluation' is the market's rational assessment of cyclical risk. Therefore, it is fairly valued relative to near-term macro headwinds but deeply undervalued if one assumes the housing cycle will eventually recover.
TMHC is a good buy for a specific type of investor: a patient value investor willing to accept high volatility for a potential cyclical turnaround. The valuation is compelling with a forward P/E of 9.81x and a P/B below 1, and the balance sheet is exceptionally strong with minimal debt. However, it is not a good buy for those seeking stability or short-term gains, given its 58% higher volatility than the market and its severe underperformance over the past year. The key is believing the housing market will stabilize before the company's fundamentals deteriorate.
TMHC is suitable primarily for a long-term investment horizon of 3-5 years. Its value proposition is based on the eventual recovery of the housing cycle and the realization of its asset value, which is a slow, macro-dependent process. Its high volatility (beta 1.581) and lack of dividend make it a poor fit for short-term trading or income portfolios. Investors should be prepared to hold through potential further downturns to capture the full cyclical upswing. A minimum holding period of 18-24 months is suggested to allow for the investment thesis to play out.